Emergent BioSolutions Inc.

What they do

The company operates through three segments: Commercial Products (NARCAN and KLOXXADO naloxone nasal sprays), MCM Products (anthrax and smallpox vaccines/therapeutics sold primarily to the U.S. government), and Services (contract development and manufacturing, or CDMO). It holds a portfolio of 11 marketed products, 10 of which it owns, and a pipeline of clinical- and preclinical-stage candidates addressing chemical, biological, radiological, nuclear, and emerging infectious disease threats.

Revenue drivers

• Commercial Products (Naloxone) — Generates revenue from sales of NARCAN Nasal Spray 4 mg (OTC and prescription) and KLOXXADO Nasal Spray 8 mg (prescription) to retail pharmacies, government entities, and community organizations. In 2025, total company revenue was $742.9M, with naloxone being a significant portion, though competition from generics is pressuring this segment.
• MCM Products (Anthrax & Smallpox) — Includes anthrax MCMs (BioThrax, CYFENDUS, ANTHRASIL, Raxibacumab) and smallpox MCMs (ACAM2000, CNJ-016 VIGIV, BAT). Revenue is driven by U.S. government procurement contracts; recent Q2 2026 included a $52.7M ACAM2000 modification and a $64.5M BAT modification.
• Services (CDMO) — Provides development services, drug substance manufacturing, and drug product packaging to external customers. This segment contributes to overall revenue but is smaller than the product segments.

Recent performance

For Q2 2026, total revenue was $234.3M, up 66% year-over-year, driven by accelerated U.S. government MCM contract modifications. However, GAAP net loss was $180.2M (versus $12.0M loss a year ago), largely due to a $191.3M non-cash impairment charge. Adjusted net income was $30.9M, up 134%, and adjusted EBITDA was $96.5M (41% margin). For the first half of 2026, revenue was $390.4M (up 8%) with a net loss of $173.4M versus net income of $56.0M in the prior-year period. In fiscal 2025, the company reported full-year revenue of $742.9M and net income of $52.6M (diluted EPS $0.93).

Strategy

Management is executing an organizational restructuring to align resources with current needs, targeting approximately $40 million in annualized savings. The company is also taking proactive steps to strengthen its financial foundation, including refinancing a term loan with a new $150 million facility and amending an asset-backed loan facility. Additionally, Emergent seeks to collaborate with AI partners for bioterrorism preparedness and continues to expand its NARCAN product line with new carrying cases and multipack configurations. The company's long-term plan centers on its multi-year transformation and its core mission of providing preparedness and response solutions for public health threats.

Risks

• U.S. government funding dependency — A substantial portion of MCM segment revenue relies on U.S. government procurement contracts; reduced funding or delays in contract awards could materially impact revenue.
• Follow-on contract risk — Inability to secure follow-on contracts upon expiration of existing USG procurement agreements for products like CYFENDUS, ACAM2000, and BAT could lead to significant revenue declines.
• Generic competition for NARCAN — Over-the-counter and prescription naloxone markets face generic and competitive pressures that could erode pricing and market share for NARCAN and KLOXXADO.
• Quality and compliance at manufacturing sites — Failure to maintain current good manufacturing practices and regulatory compliance could disrupt production, delay deliveries, and trigger government investigations or penalties.

Outlook

Management characterized Q2 2026 as a 'strong second quarter, significantly exceeding the high end of guidance' due to accelerated MCM contracts, but also noted a 'critical juncture' in the turnaround driven by naloxone business challenges. The company is implementing an organizational restructuring to preserve investment in key areas and expects annualized savings of roughly $40 million when fully implemented. Guidance for the full year was not explicitly provided in the earned release, but the multi-year plan remains focused on transformation and strengthening the financial foundation.